Articles tagged with Drug Studies
The CheckMate -9ER trial found that combining nivolumab and cabozantinib improved progression-free survival by doubling it compared to sunitinib, with a higher response rate and superior quality of life for patients. The combination treatment demonstrated meaningful efficacy benefits and manageable toxicity.
A polygenic risk score has been developed to predict drug-induced liver injury, using genomic data and organoid models. The score can identify patients at risk of liver damage, allowing for safer medication choice and dosage.
A study presented at ESMO 2020 found significant variations in access to cancer medicines and clinical trials across European countries. Western European nations tend to have more clinical trials, while Eastern and Central European countries face barriers due to limited infrastructure and resources.
A study by Vanderbilt University Medical Center found that only 54% of medical practitioners have prescribed pre-exposure prophylaxis (PrEP) to HIV-vulnerable patients, highlighting a need for increased adoption of the preventive medication.
The University of Cincinnati researchers found that Angiotensin II levels were normal in COVID-19 patients, contradicting the theory that the virus disrupts the Renin-Angiotensin-Aldosterone System. The study suggests that supplementation with synthetic angiotensin (1-7) may be a potential therapeutic target for treating COVID-19.
A $11.4 million NIH grant has funded the advancement of a novel drug candidate, SBP-9330, targeting a neuronal signaling pathway underlying addictive behaviors to treat nicotine addiction. The drug is expected to be effective in reducing nicotine self-administration and may broaden its indication to other types of addiction.
Researchers found that taking azithromycin with QT-prolonging drugs increases the risk of cardiac events by 40%. These events include fainting, heart palpitations, and cardiac arrest. The study suggests doctors should monitor patients taking azithromycin for these medications.
A study by Kaiser Permanente found no difference in TSH stability between patients taking desiccated thyroid products and those on synthetic levothyroxine, a surprising outcome given concerns about variability among batches of desiccated thyroid. This result has implications for patient-centered approach to managing hypothyroidism.
Researchers at UTHealth are enrolling patients in a nationwide trial testing laboratory-made antibodies and experimental treatments to prevent severe COVID-19 illness. The Phase II trial aims to evaluate the effectiveness of these treatments in non-hospitalized adults with mild COVID-19.
A large-scale clinical trial has shown that lanthanum carbonate does not reduce the risk of cardiovascular disease developing in patients with chronic kidney disease. High phosphate levels are a common problem in kidney disease and linked to cardiovascular disease, but the study found no benefit from the medication.
A new study provides a framework for guideline developers to offer specific guidance on right-sizing care, including when to start and stop treatments or screening. The recommendations are tailored for adult primary care and aim to reduce unnecessary testing and treatment, improving patient outcomes and quality of life.
Researchers found a combination of olaparib and capivasertib to be effective against advanced cancers, including those that stopped responding to chemotherapy. The treatment targets two weaknesses in cancer, DNA repair and AKT addiction, offering new hope for patients with drug-resistant cancer.
Researchers found that levodopa stabilized and improved vision in patients with advanced age-related macular degeneration (AMD), reducing the number of treatments necessary. The drug's ability to target the GPR143 receptor led to a decrease in retinal fluid and an improvement in visual acuity.
New research suggests that reducing or eliminating high blood pressure medications in COVID-19 patients who develop hypotension can prevent acute kidney injury and death. The study found that nearly 60% of patients had a history of hypertension, making it the most common co-occurring health issue.
A new study published at American Heart Association's Hypertension 2020 Scientific Sessions found that treatment to lower high blood pressure did not increase and may have decreased the risk of developing orthostatic hypotension. The study, which analyzed data from nine large clinical trials, found that more aggressive blood pressure t...
Researchers found that green light exposure reduced headache days per month by an average of about 60%, with most participants experiencing a more than 50% reduction. The study also improved patients' quality of life, including sleep and work abilities, with no reported side effects.
Scientists have developed a gene test that can predict the risk of certain medications causing liver injury. The test uses a polygenic risk score, which takes into account over 20,000 gene variants to identify individuals at higher risk. This could lead to more accurate prescribing and safer drug development.
A phase 3 global clinical trial showed a new drug boosts bone growth in children born with achondroplasia by blocking the activity of FGFR3 protein, potentially returning growth rates to normal. The experimental drug vosoritide was safe and effective in increasing bone growth over one year.
A study published in Neurology found that anticholinergic drugs may accelerate cognitive decline in older adults, particularly those at risk for Alzheimer's disease. Researchers discovered that participants taking these medications were 47% more likely to develop mild cognitive impairment over a decade.
Researchers aim to enroll patients aged 6-17 with moderate to severe PANS and evaluate the effectiveness of PANZYGA versus placebo in reducing symptoms. The study will also assess sustainability and functional impairment associated with PANS treatment.
The study aims to test the efficacy of LY-CoV555 in reducing viral load and clinical symptoms in patients with mild to moderate COVID-19. The trial will enroll 400 total patients and provide a potential new treatment option for those with compromised immune systems.
Vanderbilt University Medical Center is launching a clinical trial of promising treatments for COVID-19 in the outpatient setting as part of the ACTIV-2 protocol. The study aims to find a safe and effective treatment for non-hospitalized patients with COVID-19.
A recent clinical trial has shown that an experimental medication, AMX0035, can slow the progression of Amyotrophic lateral sclerosis (ALS) by improving functional outcomes. The study involved 137 participants with ALS and demonstrated a significant slowing of disease progression.
A new international study published in JAMA found that treating critically ill COVID-19 patients with the steroid hydrocortisone improves their chances of recovery. The study showed a 93% chance of better outcomes for patients treated with a fixed dose of hydrocortisone.
A recent study has found that corticosteroids improve the odds of survival for very sick COVID-19 patients. The REMAP-CAP trial combined data from 121 hospitals in eight countries and found a 93% probability that giving patients hydrocortisone would result in better outcomes.
The REALITY trial found that restricting blood transfusion to those with very low haemoglobin levels has no negative impact on clinical outcomes, while also saving blood. The trial showed that the restrictive strategy was non-inferior to the liberal strategy in preventing 30-day major adverse cardiac events (MACE) and was more cost-eff...
Two studies found that e-cigarettes are not effective in helping adults quit smoking, but may lead to nicotine dependence. Researchers used data from a large nationally representative longitudinal study and found that cessation rates did not differ between e-cigarette users and closely matched smokers who did not use e-cigarettes.
A study published in the New England Journal of Medicine found that JAK inhibitors improved developmental milestones in patients with AGS, a rare genetic disorder. The treatment showed promise in improving neurological function, particularly in children who received higher doses.
Researchers at Vanderbilt University Medical Center are conducting a clinical trial to determine the effectiveness of nasal saline irrigations in reducing COVID-19 symptoms and transmissibility. The study aims to explore if nasal hygiene can be used as an affordable and accessible treatment option.
A Yale clinical trial is using an automated bilingual computerized approach to screen for and intervene with high-risk drinking behaviors among Latino patients in emergency departments. The study aims to explore unique differences within Latino subgroups and advance understanding of addressing health disparities in alcohol use disorders.
A new study found that an educational mailing did not increase the uptake of stroke prevention drugs among patients with atrial fibrillation. The IMPACT-AFib trial involved over 47,000 patients and showed no significant difference in oral anticoagulant initiation between the intervention group and control group.
A randomized trial found that continuing common heart medications in COVID-19 patients did not negatively impact their health. The trial enrolled 659 patients and showed no significant difference in the number of days alive and out of hospital between those who continued and suspended their medications.
A recent study by the Centre for Health Evaluation and Outcome Sciences found that one quarter of prescription drugs in Canada were reported in shortage during a study period. The average length of a shortage was five months, with markets with single generic manufacturers being the most vulnerable to shortage.
The LoDoCo2 trial found that low-dose colchicine significantly reduced the risk of major cardiovascular events by almost one-third in patients with chronic coronary disease. The study also showed that colchicine was well-tolerated over the long-term, with no significant adverse effects.
Two randomized controlled studies demonstrate that SGLT2 inhibitors can slow CKD progression across all patient groups, not just those with diabetes. The DAPA-CKD trial found a significant reduction in kidney function decline and end-stage disease with dapagliflozin treatment.
The ATPCI trial found that trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes. Trimetazidine protects against myocardial ischaemia by improving the heart's metabolism, but its benefits were limited.
A large study of over 260,000 participants found no evidence that blood pressure lowering drugs increase the risk of cancer. The research analyzed data from 31 trials and investigated five antihypertensive drug classes, including ACE inhibitors and beta blockers.
The EAST-AFNET 4 trial found that early rhythm control therapy reduces cardiovascular complications and death in patients with atrial fibrillation. Rhythm control therapy delivered soon after diagnosis can improve outcomes, including reduced risk of severe cardiovascular complications.
The PARALLAX trial found that sacubitril/valsartan reduces NT-proBNP levels by 16.4% compared to individualised medical therapy, indicating improved heart failure severity. However, functional capacity was not improved, with no significant difference in six-minute walk distance between groups at week 24.
A large Australian-Dutch trial confirmed low-dose colchicine significantly reduced cardiovascular death, heart attack, and stroke in patients with chronic coronary disease. Colchicine was safe and well-tolerated over the long-term, making it a potential cornerstone treatment alongside aspirin and statins.
Researchers from Brigham and Women's Hospital have discovered that senolytic drugs can rejuvenate older organs, reducing inflammation and improving survival rates. The study suggests that these drugs could help close the gap between organ demand and supply, benefiting patients on transplant waitlists.
A Yale University study finds that the brain takes time to normalize after abstaining from alcohol, making 'one day at a time' an effective recovery strategy. The study also suggests potential medications to aid in long-term abstinence.
Researchers developed a synthetic compound called CPTX that improved symptoms of Alzheimer's disease, spinal cord injury, and cerebellar ataxia in mice. The protein restored neural connections, increased excitatory transmission, and promoted memory formation.
Research reveals that HIV studies are often designed with an unrepresentative population, leading to a lack of effective solutions for diverse groups. The study's findings highlight the need for more inclusive research methods to address health inequalities and improve patient outcomes.
Researchers at the University of South Carolina have found that Δ9-tetrahydrocannabinol (THC) can completely prevent Acute Respiratory Distress Syndrome (ARDS) caused by Staphylococcal enterotoxin. The study suggests a possible treatment for ARDS caused by COVID-19.
The Phase I/II LIBRETTO-001 trial found that selpercatinib achieved durable objective responses in the majority of participants with RET gene fusions, including an ORR of 85% in previously untreated patients. The study also showed promising results in patients with brain metastases and thyroid cancers.
Research found occupational exposures to pollutants, including burning wood and vehicle exhaust, were associated with abnormal heart function and structure. Long-term exposure to these pollutants may increase the risk of cardiovascular disease, especially among low-income occupations.
A new meta-analysis of published studies on hydroxychloroquine for COVID-19 treatment finds no mortality benefit, while combining it with azithromycin is associated with a 27% increased risk. The study supports current clinical recommendations against using these drugs for COVID-19 patients.
A University of Cincinnati-led study suggests that a specific selective serotonin reuptake inhibitor (SSRI) may be beneficial in treating childhood anxiety disorders. The treatment showed promise in reducing anxiety symptoms in adolescents with generalized anxiety disorder.
A new clinical trial, TAILOR-PCI, found that genetic testing can identify patients who may benefit from alternative antiplatelet therapy. The study showed a statistically significant 40% reduction in blood clotting events in patients with the CYP2C19 gene variation who received genotype-guided treatment.
Most adults with systemic lupus erythematosus (SLE) and common forms of arthritis are not at increased risk of hospitalization from COVID-19, despite taking immunosuppressive medications. Hospitalization rates for these groups are similar to those for the general population.
A recent trial found that genetic testing can significantly reduce the risk of serious cardiovascular events after balloon angioplasty. The study used personalized genetic testing to identify patients with a specific gene variation that affects the activation of antiplatelet medication, resulting in a 34% reduction in adverse events.
Researchers at Scripps Research have identified a new class of compounds that can restart cellular production of VEGF-A, a key factor in rebuilding blood vessels and muscle in damaged heart tissue. The discovery has the potential to revolutionize the treatment of heart failure and other cardiovascular diseases.
Researchers at IKBFU have discovered that heather is a rich source of biologically active compounds with various medicinal properties. The study found that the budding stage of heather plants contains the highest amount of flavonoids, which are of great medicinal value.
A Danish study found that none of the most common high blood pressure medications increase depression risk, while nine lowered it. The medications enalapril and ramipril, amlodipine and other calcium antagonists, and beta-blockers like propranolol lowered depression risk.
Vaxine Pty Ltd is accelerating clinical testing of its COVAX-19 vaccine using Microsoft's AI for Health program. The company aims to collect and analyze trial data in real-time, reducing the traditional waiting period.
Researchers have discovered stable, synthetic STING agonists that induce anticancer immune responses in mice. These non-nucleotide small molecule STING agonists show robust anti-tumor activities and may represent an attractive approach for targeting the STING pathway.
A European research alliance studied 252 adults at risk of spinocerebellar ataxia, tracking the development of symptoms over several years. The study provides valuable data for prevention studies and highlights the need for additional biomarkers to detect ataxia early.
Researchers found that COVID-19 patients with hypoxia responded positively to icatibant treatment, with improved oxygen levels and reduced need for supplemental oxygen. A follow-up study is underway to explore the effectiveness of a new drug, lanadelumab, which may offer longer-lasting benefits.
Biomedical scientists have discovered that diethylcarbamazine directly targets parasitic worms with a temporary paralysis, allowing the host's body to flush out the parasites. This breakthrough could lead to better predictability of resistance development and more effective treatment outcomes for patients.